Formulary guidance and transparency from P&T to point of care

Trends That Matter for Heart Disease Treatment

Posted by Matt Breese on Aug 31, 2017

Find me on:


In our weekly Trends that Matter series, we provide engaging infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is potential developments in the area of heart disease treatment.

Cardiovascular disease has typically been treated by methods that focus on lowering cholesterol or reducing blood pressure. However, a recent study has indicated that reducing inflammation levels may help prevent heart attack patients from experiencing a stroke or a second heart attack.

According to Ned Pagliarulo, Associate Editor at BioPharmaDIVE Novartis' drug canakinumab proposes a new way to treat heart disease: 

"Results from a large trial of canakinumab, currently marketed by Novartis as Ilaris for several inherited diseases, showed the drug significantly reduced cardiovascular risk by 15% compared to placebo."

Novartis does not currently have regulatory approval for canakinumab as a heart treatment. In addition, there is industry concern over the high drug cost. 

To learn more about this topic, read the clinical report "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" in the New England Journal of Medicine. 

Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter

Topics: Specialty